Gonadal‐pituitary Hormone Levels in Gynaecomastia

I, McFadyen; Bolton, A.E.; Cameron, E. H. D.; Hunter, W. M.; Raab, Gillian M.; Forrest, A. P. M.

doi:10.1111/j.1365-2265.1980.tb01025.x

Cited by 16 publications

(6 citation statements)

References 20 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The exact cause of the increased E-2 levels is unclear. Disturbed Leydig cell function (Weinstein et al, 1974) or increased production of E-2 by Sertoli cells (McFadyen et al, 1980) have been proposed as probable reasons, the latter possibly due to previously demonstrated increases in serum gonadotrophins (Fossii et al, 1985(Fossii et al, , 1986. Increased E-2 levels, together with relatively low T levels, have been demonstrated in testicular cancer patients as a reason for reversible gynaecomastia during the first year after treatment (Saeter et a/., 1987).…”

Section: Discussionmentioning

confidence: 98%

Serum Levels of Sex Hormone Binding Globulin and Oestradiol in Patients with Testicular Cancer

Fosså

Haug

1990

British Journal of Urology

View full text Add to dashboard Cite

Serum testosterone (T), oestradiol (E-2) and sex hormone binding globulin (SHBG) were measured in 84 orchiectomised testicular cancer patients before further treatment and 4 to 6 and 12 to 15 months after therapy. Patients were divided into 3 groups according to treatment: Group 1: cisplatin-based chemotherapy (27 patients); Group 2: abdominal radiotherapy (32 patients); Group 3: no antiproliferative treatment (chemotherapy/radiotherapy) (25 patients). Between 4 and 6 months after antiproliferative treatment, particularly after chemotherapy, a reversible significant increase in E-2 and SHBG was observed. Patients without antiproliferative treatment showed no significant changes in their comparable hormone levels; 15% of all normal T values were associated with elevated levels of SHBG and E-2. Although the aetiology of these hormonal changes remains unknown, they may be related to the clinical symptoms of hypogonadism displayed by 10 to 30% of patients undergoing treatment for testicular cancer.

show abstract

Section: Discussionmentioning

confidence: 98%

Serum Levels of Sex Hormone Binding Globulin and Oestradiol in Patients with Testicular Cancer

Fosså

Haug

1990

British Journal of Urology

View full text Add to dashboard Cite

show abstract

“…Disturbed Leydig cell function with production of oestradiol in response to high serum LH levels is possible in some patients (Weinstein et al, 1974). Increased oestradiol output by Sertoli cells in response to increased FSH levels has also been indicated (Forbes, 1978;McFadyen et al, 1980). During combination chemotherapy, patients develop a state of relative malnutrition.…”

Section: Discussionmentioning

confidence: 99%

“…However, not all patients who develop gynaecomastia after treatment for testicular cancer have active disease. Some reports have described gynaecomastia as a complication of previous chemotherapy (Trump, 1982;Trump et al, 1982;Turner et al, 1982;Tseng et al, 1985) or radiotherapy (McFadyen et al, 1980). Gynaecomastia has also been described after zhemotherapy for multiple myeloma (Schorer et al, 1978;Large et al, 1983), Hodgkin's disease (Schorer et al, 1978;Sherins et al, 1978) and non-Hodgkin's lymphoma (Schorer et al, 1978;Glass and Beremberg, 1979;Trump et al, 1982).…”

mentioning

confidence: 99%

Gynaecomastia Following Cytotoxic Therapy for Testicular Cancer

Sæter

Fosså

Norman

1987

British Journal of Urology

View full text Add to dashboard Cite

Sixteen patients in complete remission after chemotherapy or radiotherapy for testicular cancer developed gynaecomastia which appeared 2 to 9 months after the end of therapy and had a mean duration of 4.8 months. These patients had statistically significant higher levels of oestradiol, FSH and oestradiol/testosterone ratio than a control group without gynaecomastia that had received similar treatment. Both groups tended to have testosterone levels in the lower normal range and all patients had normal levels of beta-HCG, prolactin and progesterone. The gynaecomastia in our patients was probably the result of an absolute increase in oestradiol or an increase relative to testosterone. Cytotoxic therapy affects both spermatogenesis and Leydig cell function, with a resultant rise in gonadotrophins which may in turn increase testicular oestrogen secretion. In testicular cancer patients, gynaecomastia may be a sign of tumour activity but it may also be caused by hormonal changes resulting from cytotoxic therapy. It is our experience that the latter treatment-related type is harmless, transient and unrelated to the patient's prognosis.

show abstract

“…Previous studies on the circulating levels of pituitary and gonadal hormones have failed to demonstrate differences between pubertal boys with and without gynecomastia [9,14,15,211. A 24-h mean level of prolactin and an absolute increase in the area under the 24-h E-2 profile has been described in a group of gynecomastic boys [ l l , 121; nevertheless, no differences existed in regard to absolute E-2 values [ 101.…”

Section: Discussionmentioning

confidence: 99%

Role of Testosterone and Dihydrotestosterone in Spontaneous Gynecomastia of Adolescents

Villalpando

Mondragón

Barron

et al. 1992

Archives of Andrology

View full text Add to dashboard Cite

To test a possible hormonal mechanism of gynecomastia at puberty, a group of pubertal spontaneous gynecomastia (PSG) and healthy young volunteers (HYV), Tanner's stage 11-V, were studied. Peripheral blood samples were obtained for measuring follicle stimulating hormone (FSH), luteinizing hormone (LH), prolactin (PRL), testosterone (T), dihydrotestosterone (DHT), estradiol (E-2) and estrone (E-I).No difference was established in steroids in pituitary hormonal concentration when both groups were compared on a sexual stage-matched control basis, except for T 2 SD in 519 subjects of PSG and DHT 2 SD in all of PSG. The T:DHT ratio varied from 5.0 to 15.4 in PSG and from 0.42 to 2.224 in HYV. Whether spontaneous gynecomastia might exist in an enzimatic blockade of Sa-reductase and whether a decrease in the T:DHT ratio might favor the estrogen action for the progression of breast enlargement deserve further analysis.

show abstract

Gonadal‐pituitary Hormone Levels in Gynaecomastia

Cited by 16 publications

References 20 publications

Serum Levels of Sex Hormone Binding Globulin and Oestradiol in Patients with Testicular Cancer

Serum Levels of Sex Hormone Binding Globulin and Oestradiol in Patients with Testicular Cancer

Gynaecomastia Following Cytotoxic Therapy for Testicular Cancer

Role of Testosterone and Dihydrotestosterone in Spontaneous Gynecomastia of Adolescents

Contact Info

Product

Resources

About